CVS agrees to pay $315 million in opioid and false claims settlement

Traders Union
All News
Financial News
CVS opioid settlement

Highlights

CVS Pharmacy Inc. will pay $315 million to settle allegations of illegally dispensing opioids and submitting false claims to Medicare and federal healthcare programs.
The U.S. Department of Justice alleges CVS filled unlawful opioid prescriptions due to corporate incentive policies, inadequate staffing, and flawed internal controls, breaching both pharmacy law and fraud statutes.
As part of the settlement, CVS must comply with a DEA agreement requiring new reporting hotlines and enhanced oversight of controlled-substance dispensing and prescriber evaluations.

Settlement terms and alleged dispensing failures

As reported by U.S. Department of Justice, CVS Pharmacy Inc. and related entities are agreeing to pay $315 million to resolve allegations that they illegally filled prescriptions for opioids and other controlled substances, then sought reimbursement for many of those prescriptions from Medicare and other federal healthcare programs.

The government’s complaint, filed on Dec. 13, 2024 in the U.S. District Court for the District of Rhode Island, alleges that CVS knowingly filled prescriptions that lacked a legitimate medical purpose, were not valid, or were not issued in the usual course of professional practice. It alleges the company dispensed excessive quantities of opioids, filled opioid prescriptions too early, and handled so-called trinity prescriptions, a combination of an opioid, a benzodiazepine, and a muscle relaxant that authorities describe as dangerous and prone to abuse.

Federal authorities also allege CVS filled controlled-substance prescriptions from pill mill prescribers and that pharmacists did so despite red flags indicating a high likelihood that the prescriptions were unlawful or medically unnecessary. Many of those prescriptions were ultimately billed to federal healthcare programs, forming the basis for the False Claims Act allegations.

The complaint further alleges the violations stemmed from corporate performance metrics, incentive compensation and staffing policies that prioritized profit over patient safety. It says CVS did not employ enough pharmacists to serve patients, meet legal obligations and satisfy internal targets, and that some policies prevented pharmacists from warning colleagues about problematic prescribers.

In addition to the financial payment, CVS is entering into a memorandum of agreement with the DEA covering future obligations for dispensing controlled substances. The agreement requires the company to establish a hotline for employees and the public to report suspected illegal dispensing, monitor pharmacy dispensing patterns proactively, and create a process to evaluate prescribers suspected of illegal prescribing.

Regulatory impact and whistleblower case

Justice Department and DEA officials say the settlement is intended to strengthen patient protections while reinforcing enforcement against unlawful opioid dispensing. The case adds to continuing federal scrutiny of pharmacies’ compliance systems as regulators press for tighter controls over controlled-substance prescribing and fulfillment.

For the pharmacy sector, the matter underscores the legal and operational risks tied to staffing, prescription review procedures and reimbursement claims involving federal health programs. The settlement also shows how compliance failures in controlled-substance dispensing can expand beyond drug enforcement issues into broader fraud liability when prescriptions are billed to the government.

The civil settlement also resolves a whistleblower lawsuit filed by former CVS employee Hillary Estright under the False Claims Act’s qui tam provisions. The United States intervened in that case, and the share of any recovery due to the private whistleblower has not yet been determined.

Our earlier report on the Justice Department’s “Joint Disruption Week” described a coordinated international crackdown on West Africa-based online scam networks, leading to arrests, device seizures, and the removal of millions of scam-linked social media accounts. The article also highlighted how investigators and private-sector partners shared intelligence to identify suspected scam centers and potentially freezable funds, amid rising reported losses from investment and cryptocurrency-related fraud.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.